gene

CSF1R

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CSF1R: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

700Connections

6Hypotheses

14Analyses

50Outgoing

50Incoming

0Experiments

20Debates

Summary

Gene profile: CSF1R — Colony Stimulating Factor 1 Receptor

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	CSF1R
Full Name	Colony Stimulating Factor 1 Receptor
Chromosome	5q32
Protein Type	Receptor
Function	Upon ligand binding, CSF1R undergoes
Primary Expression	Microglia, Macrophages, Osteoclasts, Placenta
Molecular Weight	107.6 kDa
Amino Acids	972 aa
Pathways	PI3K
UniProt ID	P07333
NCBI Gene ID	1436
Ensembl ID	ENSG00000182578
OMIM	164770
GeneCards	CSF1R
Human Protein Atlas	CSF1R
Associated Diseases	Als, Alzheimer, Anxiety, Atherosclerosis, cancer
Known Drugs/Compounds	dasatinib, KETAMINE, nicotinamide, NICOTINAMIDE, PLX3397, PLX5622
Interactions	ABL1, ABL2, ACHE, ACT001, Actin, AD
SciDEX Hypotheses	CSF1R Inhibition-Mediated Microglial Replacement a
KG Connections	700 knowledge graph edges
Databases	GeneCards HPA STRING

🧬 3D Structure Comparison — CSF1R Experimental (PDB) vs Predicted (AlphaFold) — click to expand

📄 Experimental Structure

4R7H — X-ray / Cryo-EM

🔮 AI Predicted Structure

P07333 — AlphaFold

Left: Experimental structure from RCSB PDB | Right: AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (10)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    CSF1R["CSF1R"]
    CSF1R -->|"regulates"| microglia["microglia"]
    CSF1R -->|"activates"| Leukemia["Leukemia"]
    CSF1R -->|"activates"| Als["Als"]
    CSF1R -->|"activates"| Ms["Ms"]
    CSF1R -->|"inhibits"| Depression["Depression"]
    CSF1R -->|"activates"| Carcinoma["Carcinoma"]
    CSF1R -->|"activates"| Cancer["Cancer"]
    CSF1R -->|"activates"| Tumor["Tumor"]
    PLX3397["PLX3397"] -->|"inhibits"| CSF1R
    dasatinib["dasatinib"] -->|"inhibits"| CSF1R
    PLX5622["PLX5622"] -->|"inhibits"| CSF1R
    TYK2["TYK2"] -->|"contributes to"| CSF1R
    PTK2B["PTK2B"] -->|"contributes to"| CSF1R
    IL7R["IL7R"] -->|"contributes to"| CSF1R
    JAK2["JAK2"] -->|"activates"| CSF1R
    PDGFRB["PDGFRB"] -->|"activates"| CSF1R
    ETV6["ETV6"] -->|"expressed in"| CSF1R
    NTRK3["NTRK3"] -->|"contributes to"| CSF1R

Outgoing (462)

Target	Relation	Type	Str
benchmark_ot_ad_answer_key:CSF1R	data_in	dataset_row	0.00
ds-83b31ef18d49	provides_data_for	dataset	1.00
CSF1R-related Leukoencephalopathy	causes	disease	0.95
Alzheimer'S	therapeutic_target	disease	0.85
Microglial Activation	modulates	process	0.85
neurons	expressed_in	cell_type	0.85
SOLUBLE CSF1R	cleaves	protein	0.85
neurodegeneration	inhibits	disease	0.80
tumor-associated macrophages	regulates	cell_type	0.80
Immune Cell Infiltration	associated_with	process	0.80
Als	activates	disease	0.75
astrocytes	expressed_in	cell_type	0.75
neuroinflammation	inhibits	disease	0.75
neuroinflammation	activates	disease	0.75
NEURONS	mediates	cell_type	0.70
MACROPHAGE	expresses	cell_type	0.70
MACROPHAGE	markers	cell_type	0.70
CX3CR1	markers	gene	0.70
STING	activates	gene	0.70
IBA1	activates	gene	0.70
CXCL10	inhibits	gene	0.70
STING	causes	gene	0.70
SQSTM1	activates	gene	0.70
MICROGLIA	protects_against	cell_type	0.70
JAK	activates	gene	0.70
PDGF	associated_with	gene	0.70
PDGF	expressed_in	gene	0.70
ULK1	activates	gene	0.70
CX3CR1	activates	gene	0.70
MICROGLIA	mediates	cell_type	0.70
LAMP1	activates	gene	0.70
Blood-Brain Barrier	activates	pathway	0.70
COMPLEMENT PATHWAY	inhibits	pathway	0.70
TAU	inhibits	protein	0.70
APOE4 effects	inhibits	pathway	0.70
MICROGLIA	inhibits	gene	0.70
stem cells	expressed_in	cell_type	0.70
microglia	regulates	cell_type	0.70
microglia	expressed_in	cell_type	0.70
Schwann cells	expressed_in	cell_type	0.70
NICOTINAMIDE	inhibits	drug	0.70
Alzheimer	associated_with	disease	0.65
Cancer	therapeutic_target	disease	0.65
Atherosclerosis	associated_with	disease	0.65
ALS	associated_with	disease	0.65
Cancer	inhibits	disease	0.65
Als	therapeutic_target	disease	0.65
Alzheimer	activates	disease	0.65
Ms	activates	disease	0.65
Ms	contributes_to	disease	0.65

Incoming (238)

Source	Relation	Type	Str
benchmark_ot_ad_answer_key:CSF1R	data_in	dataset_row	0.00
ds-83b31ef18d49	data_in	dataset	1.00
PLX3397	inhibits	drug	0.90
h-var-799795f6af	targets_gene	hypothesis	0.90
MICROGLIA	associated_with	cell_type	0.74
dasatinib	inhibits	drug	0.72
AIF1	activates	gene	0.70
BECN1	activates	gene	0.70
ATG5	activates	gene	0.70
APOE	activates	gene	0.70
APP	activates	gene	0.70
PLX5622	inhibits	drug	0.70
PARP1	inhibits	gene	0.70
AMYLOID	associated_with	gene	0.66
BDNF	associated_with	gene	0.66
ASTROCYTE	activates	cell_type	0.65
MACROPHAGES	produces	cell_type	0.65
CANCER	associated_with	disease	0.65
ASTROCYTE	associated_with	gene	0.65
BAX	treats	gene	0.65
MACROPHAGE	interacts_with	cell_type	0.65
CD2AP	activates	gene	0.65
NEURONS	treats	cell_type	0.65
MICROGLIA	regulates	cell_type	0.65
NEUROINFLAMMATION	treats	phenotype	0.65
NEURONS	inhibits	cell_type	0.65
ALZHEIMER'S DISEASE	associated_with	disease	0.64
GENES	associated_with	gene	0.60
SYNAPSE	associated_with	gene	0.60
DISEASE-ASSOCIATED MICROGLIA	associated_with	gene	0.60
HDAC	activates	gene	0.60
STROKE	activates	gene	0.60
IL-1	activates	gene	0.60
GABA	activates	gene	0.60
DEPRESSION	associated_with	gene	0.60
CRLF2	activates	gene	0.60
ABL1	expressed_in	gene	0.60
CCL2	expressed_in	gene	0.60
dasatinib	targets	drug	0.60
CCL2	associated_with	gene	0.60
ABL2	expressed_in	gene	0.60
CREB	inhibits	gene	0.60
CRLF2	contributes_to	gene	0.60
FLT3	contributes_to	gene	0.60
DEPRESSION	inhibits	gene	0.60
ALZHEIMER	associated_with	gene	0.60
PHAGOCYTOSIS	associated_with	gene	0.60
COMPLEMENT	associated_with	gene	0.60
ACHE	activates	gene	0.60
AΒ	inhibits	gene	0.60

Targeting Hypotheses (6)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
CSF1R Inhibition-Mediated Microglial Replacement as a State	0.898	neurodegeneration	How do different microglial subtypes (DA
CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion	0.808	neurodegeneration	TREM2 agonism vs antagonism in DAM micro
TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming	0.748	neurodegeneration	Gene expression changes in aging mouse b
CSF1R Partial Agonism Combined with TREM2 Activation for ALS	0.535	neurodegeneration	Microglial subtypes in neurodegeneration
TREM2 on Perivascular Macrophages Senses Aβ and Drives SPP1	0.496	neurodegeneration	How do perivascular cells specifically r

CSF1R Inhibition Reversal Window Depends on Microglia Replac	0.395	neurodegeneration	What is the optimal therapeutic window f

Mentioning Analyses (14)

Scientific analyses that reference this entity

Does Alectinib truly bind C1q directly with high affinity, or is this an experim

molecular biology | 2026-04-17 | 10 hypotheses Top: 0.455

Microglial subtypes in neurodegeneration — friend vs foe

neurodegeneration | 2026-04-17 | 7 hypotheses Top: 0.685

How do different microglial subtypes (DAM vs inflammatory vs homeostatic) transi

neurodegeneration | 2026-04-16 | 5 hypotheses Top: 0.919

How do B cells mechanistically orchestrate tolerance to AQP4 and prevent autoimm

neuroinflammation | 2026-04-13 | 2 hypotheses Top: 0.683

Epigenetic reprogramming in aging neurons

neurodegeneration | 2026-04-04 | 9 hypotheses Top: 0.914

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (20)

Multi-agent debates referencing this entity

The fundamental premise remains unvalidated despite extensive mechanistic specul

closed · Rounds: 4 · Score: 1.00 · 2026-04-19

Analyze the spectrum of microglial activation states (DAM, homeostatic, inflamma

closed · Rounds: 4 · Score: 0.50 · 2026-04-18

The fundamental premise remains unvalidated despite extensive mechanistic specul

closed · Rounds: 4 · Score: 0.50 · 2026-04-18

The debate framework mentioned multiple microglial subtypes but no analysis was

unknown · Rounds: 4 · Score: 1.00 · 2026-04-18

The title suggests B cells actively maintain tolerance to AQP4, but the specific

closed · Rounds: 4 · Score: 0.66 · 2026-04-13

The title suggests B cells actively maintain tolerance to AQP4, but the specific

closed · Rounds: 4 · Score: 0.79 · 2026-04-13

Mitochondrial transfer between neurons and glia?

closed · Rounds: 4 · Score: 0.71 · 2026-04-12

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

closed · Rounds: 4 · Score: 0.69 · 2026-04-12

How does microglial priming contribute to early Alzheimer's disease pathology? F

closed · Rounds: 4 · Score: 0.80 · 2026-04-12

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small

closed · Rounds: 6 · Score: 0.84 · 2026-04-12

Related Research

Hypotheses and analyses mentioning CSF1R in their description or question text

CSF1R Inhibition Reversal Window Depends on Microglia Replacement Kinetics

Score: 0.395 · neurodegeneration · 2026-04-22

## Mechanistic Overview CSF1R Inhibition Reversal Window Depends on Microglia Replacement Kinetics starts from the claim

CSF1R

Understanding Entity Pages

Summary

Wiki Pages (10)

CSF1R — Colony Stimulating Factor 1 Receptor

CSF1R Inhibitors for Parkinson's Disease

CSF1R-Targeted Microglia Therapy

Pexidartinib (PLX3397) CSF1R Inhibitor Parkinson's Disease Trial (NCT04888966)

CSF1R Modulation Therapy: Microglia Reset Protocol

CSF1R Inhibitors for Neurodegeneration

CSF1R Modulation Therapy

CSF1R Protein (Colony Stimulating Factor 1 Receptor)

PLX5622 CSF1R Inhibitor Trial in Early Alzheimer's Disease

CSF1R-Inhibited Microglia

Pathway Diagram

Outgoing (462)

Incoming (238)

Targeting Hypotheses (6)

Mentioning Analyses (14)

Does Alectinib truly bind C1q directly with high affinity, or is this an experim

Microglial subtypes in neurodegeneration — friend vs foe

How do different microglial subtypes (DAM vs inflammatory vs homeostatic) transi

How do B cells mechanistically orchestrate tolerance to AQP4 and prevent autoimm

Epigenetic reprogramming in aging neurons

Neuroinflammation and microglial priming in early AD

Neuroinflammation and microglial priming in early Alzheimer's Disease

Gene expression changes in aging mouse brain predicting neurodegenerative vulner

Circuit-level neural dynamics in neurodegeneration

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

TDP-43 phase separation therapeutics for ALS-FTD

4R-tau strain-specific spreading patterns in PSP vs CBD

TREM2 agonism vs antagonism in DAM microglia

Mitochondrial transfer between neurons and glia

Experiments (0)

Related Papers (0)

Debates (20)

The fundamental premise remains unvalidated despite extensive mechanistic specul

Analyze the spectrum of microglial activation states (DAM, homeostatic, inflamma

The fundamental premise remains unvalidated despite extensive mechanistic specul

The debate framework mentioned multiple microglial subtypes but no analysis was

The title suggests B cells actively maintain tolerance to AQP4, but the specific

The title suggests B cells actively maintain tolerance to AQP4, but the specific

Mitochondrial transfer between neurons and glia?

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

How does microglial priming contribute to early Alzheimer's disease pathology? F

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small

Related Research

CSF1R Inhibition Reversal Window Depends on Microglia Replacement Kinetics